Skip to main content

Infosys co-founder SD Shibulal's family sells 85 lakh company shares

SD Shibulal along with NR Narayana Murthy and five others had founded Infosys in 1981.

Family members of Infosys co-founder SD Shibulal have sold 85 lakh shares of the company between July 22-24, according to regulatory filings.

Shibulal's son Shreyas sold 40 lakh shares, "representing 0.09 per cent of Infosys Ltd by way of sale on the platform of the stock exchange on July 22, 23 and 24, 2020", an exchange filing by the company showed.

He previously held 0.66 per cent shares in Infosys and post the transaction, his holding has come down to 0.56 per cent, it added.

Gaurav Manchanda, son-in-law of the Infosys co-founder, sold 18 lakh shares (0.04 per cent), while 15 lakh shares (0.03 per cent) held by grandson Milan Shibulal Manchanda were offloaded on the same dates, additional filings by the IT Company showed. Gaurav's shareholding now stands at 0.32 per cent, while that of Milan is at 0.33 per cent.


SD Shibulal's wife, Kumari, sold 12 lakh shares (0.03 per cent) of Infosys and her shareholding is now at 0.22 per cent.

SD Shibulal along with NR Narayana Murthy and five others had founded Infosys in 1981. Shibulal served as the Chief Executive Officer and Managing Director of Infosys from 2011-2014. Prior to becoming CEO and MD, he served as the Chief Operating Officer of the company from 2007-2011.

Currently, he invests in technology startups through Axilor Ventures that he co-founded with Infosys co-founder Kris Gopalakrishnan.

Source - Moneyontrol.com

Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more